Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

New Research reveals Asia poised as Preferred Destination for Clinical Trials

Friday, March 10, 2017 7:51
% of readers think this story is Fact. Add your two cents.

(Before It's News)

SYDNEY, Mar 10 2017 - Frost & Sullivan has released a white paper, ‘Asia: Preferred Destination for Clinical Trials’, with Asia Pacific CRO Novotech presenting the findings to an audience of senior biotechnology and pharmaceutical executives in a private event at the Outsourcing in Clinical Trials – West Coast (OCT-WC 2017) conference, held Feb 22-23 in Burlingame, Ca. (USA).

Research from the paper revealed Asia as quickly becoming a clinical research powerhouse, facilitated by the availability of vast treatment-naive patient pools, exceptional clinical infrastructure and talent, and low operational costs.

- Resources, Capabilities and Speed

Elements unique to Asia include large treatment-naive patient pools, numerous clinical trial centres with advanced equipment and technology, and comparable incidence and prevalence of Western diseases. The region’s knowledgeable physicians and Key Opinion Leaders (KOLs) provide attractive environments for clinical trials and facilitate speedy trials; while low healthcare spend by many governments in Asia make clinical trials an attractive way for patients to access innovative therapies in these countries.

- Worldwide Data Acceptability

Data from clinical trials in Asia is routinely accepted as part of US Food and Drug Administration (US FDA) and European Medicines Agency (EMA) regulatory submissions. KOLs from Asia are often members of international expert groups and citable academic output from Asia is growing rapidly. Data from inspections conducted in Asia by US FDA and EMA show low levels of adverse findings versus the US or European Union (EU), indicating high international compliance to standards.

- Cost-Effectiveness

Costs in Asia for procedures, diagnostic tests and visits are generally 30-40% lower than the US and European countries.

The paper cautioned on regulatory differences in Asia, the variety of infrastructure and legal issues, and the language and cultural hurdles, but concluded that as transparency in the regulatory environment in Asia improves, the region was poised to become the preferred destination for clinical trials.

Commenting on the paper, Novotech CEO Dr. John Moller said, “Asia is an increasingly attractive destination for our biotech clients. The huge patient pools available in Asia are mainly concentrated in easily accessible urban areas, meaning that trials tend to recruit faster. In addition, the cost of trials in most Asian countries is significantly lower than the West.

“Now is an exciting time for clinical trials taking place in Asia. There are a number of large, state-of-the-art clinical trial centers in Asia that meet patient enrolment and retention goals, generate high-quality data, and are led by globally recognised key opinion leaders,” added Dr. Moller. “Regulatory processes in Asia continue to become more streamlined. Novotech is actively working with a number of regulatory authorities and clinical trial centres to improve approval processes and timelines.”

Download the Frost & Sullivan white paper ‘Asia: Preferred Destination for Clinical Trials’, available as Executive Summary (http://bit.ly/2lkrhAB) or Full Paper (http://bit.ly/2mkqHmn).

About Novotech

Headquartered in Sydney, Novotech is internationally recognised as the leading full-service contract research organisation (CRO) in the region. With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I-IV clinical trials across Asia-Pacific, and provides clinical development services for all clinical trial phases and therapeutic areas, running clinical trials in every key regional market. For more information, please visit www.novotech-cro.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the Global 1000, emerging businesses, the public sector and the investment community. To learn more, please visit www.frost.com.

Please contact:
Susan Fitzpatrick-Napier
Digital Mantra Group
T: +61 2 8218 2144 / +1 650 798 5238
E: [email protected]
W: www.digitalmantragroup.com 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.